Our company


TcLand Expression is a personalized medicine company dedicated to the development of companion diagnostics (CDx) in Immune Mediated Disorders and biomarkers in Solid Organ Transplantation.

Through its strong expertise in immunology and a preferred access to patient cohorts, TcLand Expression‘s R&D platform develops and validates non invasive multi-genes molecular diagnostic blood tests.

Our lead programs target liver transplantation and Rheumatoid Arthritis.

The most advanced programs are currently evaluated in clinical validation:

  • The RA-INF-Dx Test is a non invasive, multigene in vitro blood test intended to aid in the identification of patients with Rheumatoid Arthritis who are unlikely to show an initial response to infliximab and methotrexate combination therapy
  • The L-TolX test is a qualitative diagnostic test service using the gene expression profiling of mRNA. The L-TolX test is an in vitro diagnostic test intended to aid in the identification of liver transplant recipients with stable allograft function for whom immunosuppression withdrawal is being considered

Comments are closed.